Tilray Brands (TLRY) Non-Current Deferred Tax Liability (2018 - 2026)
Tilray Brands (TLRY) posted Non-Current Deferred Tax Liability of $7.9 million for Q1 2026, up 40.11% on a QoQ basis from $5.6 million in Q4 2025.
Tilray Brands (TLRY) Non-Current Deferred Tax Liability (2018 - 2026) Analysis & Trends
Tilray Brands' Non-Current Deferred Tax Liability history runs 9 years deep, the most recent figure standing at $7.9 million for Q1 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $7.9 million (changed N/A YoY) and the FY2025 annual result came in at $3.7 million, down 98.47% from the prior year.
- Non-Current Deferred Tax Liability was $7.9 million for Q1 2026 at Tilray Brands, up from $5.6 million in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $244.5 million in Q2 2024 and bottomed at $1.9 million in Q3 2025.
- A 5-year average of $134.8 million and a median of $165.4 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2024 — Non-Current Deferred Tax Liability soared 46.09% — and 2025, when it plunged 98.57%.
- Tilray Brands' Non-Current Deferred Tax Liability stood at $180.1 million in 2022, then dropped by 7.58% to $166.5 million in 2023, then declined by 24.32% to $126.0 million in 2024, then tumbled by 95.54% to $5.6 million in 2025, then soared by 40.11% to $7.9 million in 2026.
- Business Quant data shows TLRY's Non-Current Deferred Tax Liability at $7.9 million in Q1 2026, $5.6 million in Q4 2025, and $1.9 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Tilray Brands | 465.02 Mn | 373.06 Mn | 54.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Feb 28, 2026 | 7.88 Mn |
| Feb 28, 2026 | 7.88 Mn |
| Nov 30, 2025 | 5.62 Mn |
| Nov 30, 2025 | 5.62 Mn |
| Aug 31, 2025 | 1.94 Mn |
| Aug 31, 2025 | 1.94 Mn |
| May 31, 2025 | 3.75 Mn |
| May 31, 2025 | 3.75 Mn |
| Nov 30, 2024 | 125.98 Mn |
| Nov 30, 2024 | 125.98 Mn |
| Aug 31, 2024 | 136.23 Mn |
| Aug 31, 2024 | 136.23 Mn |
| May 31, 2024 | 244.50 Mn |
| May 31, 2024 | 244.50 Mn |
| Feb 29, 2024 | 161.04 Mn |
| Feb 29, 2024 | 161.04 Mn |
| Nov 30, 2023 | 166.45 Mn |
| Nov 30, 2023 | 166.45 Mn |
| Aug 31, 2023 | 169.63 Mn |
| Aug 31, 2023 | 169.63 Mn |